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INTRODUCTION
Warts are benign epithelial neoplasms of the skin and mu-
cosa resulting from human papillomavirus (HPV) infection.
They are a common dermatologic complaint, with an esti-
mated incidence of 10% in children and young adults (1).
Even if disease progression is naturally self-limited, the course
of the disease is unpredictable, and treatment may be neces-
sary. Several treatment methods are available for treatment
of warts; however, most methods have specific disadvantages
and side effects. Invasive methods have the drawbacks of pain
and long recovery periods. Topical management requires the
application of drugs for long durations and treatment success
is, therefore, highly dependent on patient compliance (2). 
Laser treatment is based on the principle of photodermal
or photomechanical destruction of the target tissue. Target
structures absorb monochromatic coherent light of specific
wavelength and fluence. Light energy gets converted to ther-
mal energy, thus destroying the target structure. Depending
on the pulse duration and energy density, this may result in
the coagulation (photodermal effect) or blasting (photome-
chanical effect) of these structures (2). A wart is a lesion char-
acterized by proliferation and dilation of vessels. Many stud-
ies have used 585-nm pulsed dye lasers for the treatment of
warts, with the wart blood vessels as the target tissue (1-4).
This is because hemoglobin in blood has strong absorption
peaks at wavelengths ranging from 585 to 595 nm (5). More-
over, hemoglobin has a significant, albeit more modest, ab-
sorption peak between 800 and 1,100 nm. Therefore, it has
been postulated that 1,064-nm Nd:YAG lasers could be used
in the treatment of telangiectases (5). In addition, since there
is decreased light absorption by melanin at this wavelength,
there is reduced risk of pigmentary side effects (4). Previous
studies have shown that 1,064-nm Nd:YAG lasers used at
longer widths can be used to treat telangiectasias of the lower
extremities (5), face (6), and venous lake (7). We used a long-
pulsed Nd:YAG laser in the treatment of warts, with the wart
blood vessels as the target, and evaluated clinical outcomes. 
MATERIALS AND METHODS
Patients
Over the course of 1 yr, 369 patients (mean age, 21 yr; range,
3-67 yr) (Table 1) with recalcitrant or untreated warts were
treated with a long-pulsed Nd:YAG laser. Informed written
consent was obtained from all participants before inclusion
in the study. In all, 21 patients were lost during follow up,
and therefore, the data of 348 patients were evaluated. Warts
were classified into three types-verruca vulgaris (212 patients),
deep palmoplantar warts (68 patients), and periungual warts
(68 patients). Prior to the study, photographs of all the lesions
were taken and the size of each lesion was recorded.
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Long-Pulsed Nd:YAG Laser Treatment of Warts: Report on a Series
of 369 Cases
Various treatment methods have been adopted in the management of warts; how-
ever, there is still no consensus on first-line treatment. This study was designed to
evaluate the efficacy of long-pulsed Nd:YAG laser in the treatment of warts. Over
the course of 1 yr, 369 patients with recalcitrant or untreated warts were exposed
to a long-pulsed Nd:YAG laser. The following parameters were used: spot size, 5
mm; pulse duration, 20 msec; and fluence, 200 J/cm
2. No concomitant topical treat-
ment was used. In all, 21 patients were lost during follow up; hence, the data for
348 patients were evaluated. The clearance rate was 96% (336 of the 348 treated
warts were eradicated). The clearance rate of verruca vulgaris after the first treat-
ment was very high (72.6%), whereas the clearance rate of deep palmopantar warts
after the first treatment was low (44.1%). During a median follow-up period of 2.24
months (range, 2-10 months), 11 relapses were seen (recurrence rate, 3.27%). In
conclusion, long-pulsed Nd:YAG laser is safe and effective for the removal or reduc-
tion of warts and is less dependent on patient compliance than are other treatment
options. 
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The study employed a 1,064-nm long-pulsed Nd:YAG
laser (Cutera, Inc., Brisbane, CA, U.S.A.). The following para-
meters were used: spot size, 5 mm; pulse duration, 20 msec;
and fluence, 200 J/cm2. Prior to laser treatment, warts were
treated with EMLA
� cream or a local lidocaine injection and
were peeled with a razor blade. One or two courses of slight-
ly overlapping laser pulses were applied to each wart, cover-
ing the wart itself and a 1-mm margin on the surrounding
skin. Around the third treatment date, crusts were found to
be formed on the treated parts. At 1 to 2 weeks after treat-
ment, the crusts were removed, and the warts were cleared,
leaving only a small scar (Figs. 5-7). The treatment interval
was 4 weeks, with up to four treatment sessions. Clearance
was defined as the complete absence of a clinically apparent
wart, and treatment failure was defined as a persistent lesion
after four treatments. 
RESULTS
The average number of treatment sessions required for
clearance was 1.49 (range, 1-4 sessions) (Fig. 1). At the end
of the first treatment, 64% of warts were cleared, while 96%
(336/348) of warts were cleared after the fourth treatment
(Fig. 2). Verruca vulgaris responded better than the other
types of warts and required fewer treatments for clearance
(mean, 1.35 sessions). Deep palmoplantar warts required a
mean of 1.95 sessions for clearance (Fig. 1). The clearance
rate after the first treatment was also higher in the verruca
vulgaris group (72.6%) than 64.7% in the periungual warts
group and 44.1% in the deep palmoplantar warts group (Fig.
3). The size of the warts was reduced by an average of 10%
based on the diameter. This was observed in 69.1% of the
verruca vulgaris warts, 52.5% of the periungual warts, and
27.4% of the deep palmoplantar warts. Histopathologic ex-
amination after treatment showed separation of the dermo-
epidermal junction, epidermal necrosis, and red blood cell
(RBC) extravasation. Destroyed blood vessels surrounded by
a dense inflammatory infiltrate were also shown in the der-
mis (Fig. 4). Since most (82%) patients who were anesthetiz-
ed with EMLA
� cream complained of serious pain during
treatment, local lidocaine injections were administered dur-
ing the second treatment. Other side effects included tran-
sient numbness (15%), hemorrhagic bullae (7%), hyperpig-
mentation (5%), and hypopigmentation (4%). In addition,
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Fig. 1. Average number of treatments according to subtypes of
warts.
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Fig. 2. Cumulative clearance by successive treatments.
Fig. 3. Clearance rates according to number of laser sessions per subtype.
Tx, treatment.
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Subtype
Number 
of patients
Mean age
(yr)
Male/
Female
Mean
duration (yr)
Verruca vulgaris 212 20.6 142/70 1.8
Deep palmoplantar wart 68 18.8 18/13 2.4
Periungual wart 68 22.7 8/9 2.1
Table 1. Characteristics of the subjects enrolled in this study2% of patients with periungual warts experienced nail dys-
trophy. During a median follow-up period of 2.24 months
(range, 2-10 months), 11 relapses were seen (recurrence rate,
3.3%).
DISCUSSION
Warts are very common, with an incidence of approximate-
ly 10% in children and young adults. An estimated 4-mil-
lion-patient visits were recorded in 1982 for nonvenereal warts.
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Fig. 4. Histopathological findings by H&E staining. (A) Separation of dermo-epidermal junction (×40). (B) Destroyed blood vessels in the
dermis surrounded by a dense inflammatory infiltrate (×200).
A B
Fig. 5. (A) Periungual wart. (B) Crusts were formed three days after treatment.
A B
Fig. 6. (A) Deep palmoplantar wart three days after treatment. (B) After one week. (C) After two weeks.
A B CApproximately 70% of these patients were between 10 and
39 yr of age, and 50% presented to a dermatologist. Peak
incidence occurs between the ages of 12 and 16 yr (8). Warts
often cause pain and may interfere with function. These com-
plications, along with cosmetic embarrassment and risk of
translocation to other areas of the skin, are indications for treat-
ment, which can be challenging. Effective therapy must pro-
vide reduction in pain and improvement in quality of life.
Many different types of therapy have been used in the treat-
ment of warts (9-13). Commonly used methods of physical
destruction include surgical excision, electrodesiccation, cryo-
surgery, and pulsed dye or carbon dioxide laser therapy. Chem-
ical destruction can be induced with salicylic acid, canthari-
din, formaldehyde, or glutaraldehyde, among other agents.
Chemotherapeutic agents include podophyllin, podophyllo-
toxin, 5-fluorouracil, and bleomycin. Allergic contact agents
used against warts include dinitrochlorobenzene and squaric
acid dibutyl ester. More recently, immunomodulators such
as interferon, systemic retinoids, cimetidine, and topical imi-
quimod have been used (14-16).
This prospective study evaluated the efficacy of long-pulsed
Nd:YAG lasers in the treatment of warts. The results show
that long-pulsed Nd:YAG lasers are a safe and effective app-
roach to wart treatment, with clearance rates higher than those
achieved with other common therapies. Previous studies of
cryotherapy in the treatment of warts report clearance rates
ranging from 63% to 69% (10, 17, 18). In a study using imi-
quimod, 56% of the patients reported total clearance (19).
Efficacy studies of cantharidin show success rates of approxi-
mately 80% (20). The pooled data from six randomized con-
trolled studies demonstrated a cure rate of 75% in those treat-
ed with salicylic acid compared with 48% in the control group
(21). One study performed using bleomycin prick method
demonstrated complete resolution of warts in 92% of partic-
ipants (22). 
Long-pulsed Nd:YAG lasers emit a visible light spectrum
at 1,064 nm. When a 1,064-nm long-pulsed Nd:YAG laser
is used on the skin, a short, strong laser pulse is absorbed by
red structures such as cutaneous blood vessels. As a result,
blood vessels heat up rapidly and burst. Upon blood vessel
rupture, purpura appear, which subside 5 to 7 days later. Vas-
cular lesions become pale with repeat treatment. 
The mechanism of action of a long-pulsed Nd:YAG laser
in the treatment of warts is not fully understood. Dilated ves-
sels in the papillary dermis are a characteristic feature of warts
(23). Light microscopic evaluation of treated areas at 7 days
after treatment in this study showed separation of the dermo-
epidermal junction, epidermal necrosis, and RBC extravasa-
tion. In addition to these findings, destroyed blood vessels
in the dermis were found to be surrounded by a dense inflam-
matory infiltrate. This destruction may obliterate the nutri-
ent supply to the wart or destroy the rapidly dividing epi-
dermal cells that contain HPV. Minimal destruction of the
surrounding tissue is anticipated with long-pulsed Nd:YAG
lasers.
In our study, the overall clearance rate was 96% (336 of the
348 treated warts were eradicated). The clearance rate of ver-
ruca vulgaris after the first treatment was very high (72.6%),
whereas the clearance rate of deep palmopantar warts after
the first treatment was low (44.1%). Most patients required
repeated treatments. The average number of treatments re-
quired for clearance was 1.49. During a median follow-up
period of 2.24 months (range, 2-10 months), 11 relapses were
seen (recurrence rate 3.3%). This low recurrence rate seems
to be due to the short follow-up period in this study; there-
fore, a study with a longer follow-up period and examination
of recurrence is needed. The clearance rate after pulsed dye
laser treatment, which employs the same mechanism of action
as the Nd:YAG laser, has been reported to be 48% to 92%
(1-4), while the laser used in the current study showed a high-
er clearance rate (96%). Therefore, a comparative study bet-
ween these two types of lasers is required.
Side effects noted in our study included transient pain dur-
ing treatment (82%), posttreatment numbness (15%), hem-
892 T.Y. Han, J.H. Lee, C.K. Lee, et al.
Fig. 7. (A) Verruca vulgaris on the toe. (B) Complete clearance after only one treatment session.
A Borrhagic bullae (7%), hyperpigmentation (5%), and hypopig-
mentation (4%). A crust formed in most patients and was
removed within 1 to 2 weeks. Side effects were generally mild
and did not prevent normal activity. 
In conclusion, long-pulsed Nd:YAG lasers are a safe and
effective treatment for warts, with response rates higher than
those obtained with conventional therapies. No single opti-
mal treatment has been inclicated for warts; therefore, long-
pulsed Nd:YAG lasers should be considered a reasonable addi-
tion to the therapeutic options available. Future studies exam-
ining optimal laser parameters and treatment intervals would
expand our knowledge on how best to use long-pulsed Nd:
YAG laser therapy in managing warts. 
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